Clinical trials: Major Cardiovascular Event
Microvascular Dysfunction, Hypertrophic Obstructive Cardiomyopathy
Association Between Microvascular Resistance and Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy
About 60% of patients with hypertrophic cardiomyopathy have microvascular dysfunction. Microvascular dysfunction is directly related to prognosis in hypertrophic cardiomyopathy.
- Conditions
- Microvascular Dysfunction, Hypertrophic Obstructive Cardiomyopathy, Microcirculation Resistance
- Trial name
- NCT05671367
- Where
- China
- Volunteers
- 340 people
- Sponsor
- China National Center for Cardiovascular Diseases
Diabetes Mellitus, Type 2, Myocardial Infarction
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.
Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce…
- Trial name
- NCT06017544
- Testing
- PCI
- Where
- Italy
- Volunteers
- 257 people
- Sponsor
- University of Campania Luigi Vanvitelli
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Venous Thromboembolism
StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study
The SAVER pilot is a randomized, open-label pilot study to determine the feasibility of recruitment. In addition to feasibility data, the investigators will carefully collect clinical data to determine if rosuvastatin can reduce…
- Trial name
- SAVER (NCT02679664)
- Testing
- Rosuvastatin
- Where
- 6 sites in Canada, Norway
- Volunteers
- 312 people
- Sponsor
- Ottawa Hospital Research Institute
Postoperative Complications, Cardiovascular Diseases
Comparing Traditional Risk Scores and an AI-Based Multimodal Model for Predicting Cardiovascular Events After Gastrointestinal Surgery
The goal of this observational study is to develop and evaluate an artificial intelligence (AI)-based multimodal model for predicting major cardiovascular events within 30 days after gastrointestinal surgery in adults at Bach Mai…
- Conditions
- Postoperative Complications, Cardiovascular Diseases, Digestive System Surgical Procedures
- Trial name
- GI-MACE-AI (NCT07539532)
- Where
- Vietnam
- Volunteers
- 5,000 people
- Sponsor
- Bach Mai Hospital
Heart Failure Due to Coronary Artery Disease
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
Chronic heart failure is a clinical condition caused by structural heart disease and is characterized by reduced pumping function, fluid retention, and abnormal activation of neurohormonal systems.
- Trial name
- NCT07725484
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- 21 sites in China
- Volunteers
- 1,526 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury
A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)
This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events…
- Trial name
- NCT07164833
- Testing
- BX-001N Experimental group 1, BX-001N Experimental group 2
- Where
- 8 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Bilix Co.,Ltd.
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Chronic Total Occlusion of Coronary Artery
A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter
This is a prospective, non-randomized, first-in-man investigational study, to assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional…
- Trial name
- NCT01978860
- Testing
- NovaCross, CTO
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Chanan Schneider
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Coronary Heart Disease
Cardiovascular Effects of Sporting Events
Major sporting events may have adverse cardiovascular effects in subjects with coronary heart disease. We also hypothesized that the adverse cardiovascular effects of sporting events are a result of psychobiological processes…
- Trial name
- NCT00795405
- Testing
- Exposure to sporting events, No exposure to sporting events
- Volunteers
- 38 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Acute Coronary Syndrome
Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease.
- Trial name
- GOLDEN (NCT06637657)
- Testing
- No intervention (observational study)
- Where
- Netherlands
- Volunteers
- 5,586 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hypotension, Postoperative Complications
Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery
Major adverse cardiovascular events (MACE) are a leading cause of serious complications and death following major noncardiac surgery.
- Conditions
- Hypotension, Postoperative Complications, Acute Coronary Syndrome, Heart Failure
- Trial name
- BBB (NCT02533128)
- Testing
- Liberal blood pressure management, Tight blood pressure management
- Where
- Switzerland
- Volunteers
- 458 people
- Sponsor
- Miodrag Filipovic, Prof. Dr. med.
Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)
To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.
- Trial name
- NCT05550805
- Where
- China
- Volunteers
- 5,822 people
- Sponsor
- Qilu Hospital of Shandong University
ST Elevation Myocardial Infarction
The Efficacy and Safety of Low-Level Tragus Stimulation on Heart Rate Variability, Neutrophil-Lymphocyte Ratio, and Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction (TESLA-STEMI)
The goal of this clinical trial is to learn the effect of low level tragus stimulation (LLTS) on heart rate variability (HRV), neutrophil-lymphocyte ratio, and major adverse cardiovascular events in patient with ST-segment…
- Trial name
- TESLA-STEMI (NCT06537583)
- Testing
- Parasym Neuromodulation Device (Treatment Group)
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Universitas Diponegoro
Acute Myocardial Infarction, Percutaneous Coronary Intervention
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous…
- Conditions
- Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events, Bleeding
- Trial name
- NCT02806102
- Testing
- Percutaneous coronary intervention, Dual-antiplatelet therapy
- Where
- 2 sites in South Korea
- Volunteers
- 13,000 people
- Sponsor
- Seoul St. Mary's Hospital
Pulmonary Thromboembolism
Thromboembolic Events in Severe COVID-19 Patients
The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19.
- Trial name
- COVICLOT (NCT04405869)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Major Cardiovascular Events
Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA
This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of cardiovascular outcomes in Patients Presented with myocardial infarction with nonobstructive coronary arteries.
- Trial name
- NCT06066177
- Testing
- Triglyceride glucose index TyG
- Volunteers
- 100 people
- Sponsor
- Assiut University